Insights

What FDA has said about foreign-sourced drugs in employer plans

A plain-spoken guide for employees who have been offered a prescription benefit that works differently, and want to know what to ask.

By Global Wellbeing Institute

Imagine opening your benefits packet and finding something new: a program that promises lower prices on certain medications, with the pills arriving from a pharmacy outside the United States. It sounds like good news. It might even be. But a benefit that works differently deserves a few better questions than "Where do I sign?"

This piece is general information, not legal, medical or benefits advice. Its job is simple: to lay out what the Food and Drug Administration (FDA) has actually said, so you can walk into the conversation with HR informed and unhurried.

What FDA said in its petition response

In an undated response to a citizen petition from the Aimed Alliance, a health-policy group, FDA's Center for Drug Evaluation and Research declined to issue new guidance on international importation by "alternative funding programs" (third-party arrangements that seek other funding or supply routes for certain specialty medications, sometimes including foreign pharmacies). FDA says it received the petition on March 1, 2024. The Partnership for Safe Medicines reported the response on April 8, 2026.

What did FDA's letter say? In its own words:

  • "FDA has repeatedly made clear that, in most circumstances, it is illegal for individuals to import drugs into the United States for personal use."
  • Section 804 provides a specific route for FDA-authorized programs to import certain drugs from Canada. Those programs are "sponsored by States and Indian Tribes," and FDA says alternative funding programs "as described in the Petition are not permitted to import drugs under section 804."
  • FDA warns that some drugs promoted as Canadian come from illicit sources ("in many instances," in its words).
  • FDA says its Regulatory Procedures Manual does not list the cost of an FDA-approved drug as a consideration in personal-importation cases.

FDA declined to write the guidance the petition asked for, saying it "would not be an efficient use of FDA's limited resources." The response did not announce a new enforcement action. In other words: this was a "no" to a request, not a new crackdown. That distinction matters, and it is easy to lose in the headlines.

A note on the state programs

You may hear that "the government already allows importation." Here is the accurate version. FDA authorized Florida's Section 804 program in January 2024 and Colorado's on June 15, 2026. Both are state-run. The authorization letters require FDA to grant a drug-specific Pre-Import Request before any importation. FDA's May 6, 2026 letter extended Florida's deadline to begin implementing its program to November 6, 2026, and FDA may revoke an authorization in specified circumstances. Authorization does not show that shipments have begun, and this review did not verify whether any drug has actually been imported under either program. An employer or vendor cannot rely on a state's authorization as permission for a separate importation arrangement; FDA says the alternative funding programs described in the petition cannot import under Section 804.

What changes next: a customs date to know

A separate federal change is on the calendar. CBP's October 22, 2026 final rule (91 FR 66638-66640) extends to January 20, 2027 the compliance date for formal customs entry of certain mailed goods, such as items subject to other government agencies' requirements. This follows a June 24, 2026 rule that suspended the "de minimis" exemption for mail. The October rule describes a postal informal-entry process for eligible merchandise valued at $2,500 or less, with exclusions. It also notes an optional Entry Type 13 process for eligible shipments instead of formal entry.

Does it touch prescriptions? The rule does not mention prescription drugs by name. Because drugs are regulated by FDA, some mailed prescriptions may face added customs paperwork once the date arrives, but this notice does not establish what will happen to every prescription shipment. It does not itself announce a prescription-drug ban. Its practical effect on an individual shipment will depend on the applicable entry and FDA requirements.

Will it count toward my deductible?

This is the question people ask second and should probably ask first. The American Medical Association's 2025 brief describes alternative-funding arrangements in which patient payments for excluded specialty drugs do not count toward a deductible or out-of-pocket limit. The July 2025 brief from NASTAD (a public-health association that discloses industry support for the brief) describes similar exclusions and says manufacturer copay-assistance payments generally do not count. These sources do not establish how every foreign-pharmacy benefit works. Ask the plan administrator how your own payments will be credited, and request the governing plan terms in writing.

Questions worth asking before you enroll

You do not need to be an expert. You need a short list:

  1. Where will my medication be dispensed from, and who is the dispensing pharmacy? Ask for the name and location in writing.
  2. How do I know it is the FDA-approved version? Ask what verification the program does.
  3. Do these fills count toward my deductible and out-of-pocket maximum? Ask for the plan-document language.
  4. What happens if a shipment is delayed, held or returned? Ask what the backup is, especially if customs requirements change on January 20, 2027.
  5. Can I fill the same prescription at a U.S. pharmacy instead, and what would it cost me? Ask for both numbers side by side.
  6. Who do I call if something goes wrong? Ask for a named contact, not a general inbox.
  7. Is participation optional? Ask what changes for you if you decline.

Asking is not adversarial. A good program should be glad to answer all seven.

Why we care at GIHEW

Healthcare decisions are some of the biggest ones people make, and too often they are made in a hurry, from a benefits portal, with half the picture. The Global Wellbeing Institute is a new organization, and our programs are in development. One thing we are building toward is a world where clear, trustworthy information reaches people before they have to decide, not after.

If that is a future you want to help build, we would love to hear from you. Explore the Global Wellbeing Institute, share this article with a coworker who is weighing the same choice, and tell us which questions you would like answered next.

Sources

Global Wellbeing Institute is a new organization and its programs are in development. We do not report program results.